The contractor shall provide enhanced analysis of clinical and specimen-derived data on all patients seen at VA network hospitals who have a cancer diagnosis. The contractor shall furnish a robust,…

Ended Awarded Last action

Contract number
VA24116J1098
Awardee
Awarding agency
Obligated
$72,481

Award facts

Contract value 100% obligated
$72,481.00 Current and potential, with all options
Completion date 100% complete
  • Current, with exercised options
  • Potential, with all options
Set-aside
No set-aside
Competition
Competed under SAP · 1 offer Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price
Place of performance
Jamaica Plain, MA 02130, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00001 -$1,169
Original award $73,650

Description

As the agency reported it.

The contractor shall provide enhanced analysis of clinical and specimen-derived data on all patients seen at VA network hospitals who have a cancer diagnosis. The contractor shall furnish a robust, scalable, dynamic, secure, innovative solutions of analyzing samples obtained during regular clinical care such as tissues from biopsy - using new genomic assay technology. The clia vendor shall provide emerging technologies to improve oncology care for all patients within the VA healthcare system. The contractor shall provide targeted sequencing of DNA fragments known to harbor mutations in cancer specimens (commonly referred to as a mutation panel). The number of DNA segments sequenced varies by the laboratory and assay performed. Mutations in the DNA can either be inferred against a laboratory `reference sequence or can be determined by sequencing of patient germ-line DNA obtained from adjacent normal tissue or peripheral blood. The contractors shall provide sequencing of the whole exome of cancer specimens, with mutations identified by comparison against a laboratory `reference sequence or germ-line DNA as described above. The contracotr shall provide sequencing of the cancer specimen RNA or `transcriptome . This strategy can be combined with either targeted or whole exome DNA sequencing. Products of the testing returned to the VA include all sequence data including raw test data (fast-Q, BAM, read quality files and variant call files) and a report of important mutations and their significance to be returned to the medical record. Mutations found in the tumor sample will be annotated so that clinicians can gain an understanding of their meaning. The laboratory shall specify how this annotation will be performed and in particular, what knowledge base will be used to generate the annotations. The contractor shall maintains an up-to-date knowledge base and must be able to update annotations of a patient report upon request. The contractor shall at all times maintain a secure environment and practice covering all protected health information (PHI).

Quick answers

Who was awarded contract VA24116J1098?

VA24116J1098 was awarded to Personal Genome Diagnostics Inc. by Veterans Integrated Service Network 1 (Veterans Health Administration) on April 14, 2016.

How much is contract VA24116J1098 worth?

The government has obligated $72,481 on VA24116J1098.

Is contract VA24116J1098 an order under another contract?

Yes. VA24116J1098 is a delivery order under VA24114D0176, an indefinite delivery contract.

Was contract VA24116J1098 competed?

The extent of competition for VA24116J1098 was competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login